戻る Agenda
Session 5: Updates from OPDP’s Research Team
Session Chair(s)
Lucy Rose, MBA
President
Lucy Rose and Associates, United States
Individual FDA/OPDP researchers will present findings from OPDP research studies. Attendees will gain a better understanding of the FDA/OPDP Research program and how it may contribute to knowledge, guidance, and policy development. This session is designed to educate attendees on the regulatory research work FDA has done to help inform policy and guidance development.
Learning Objective : At the conclusion of this session, participants should be able to:
- Recognize the holistic research agenda of FDA/OPDP
- Describe FDA requirements related to the use of testimonials and endorsements, including spokespersons and social media influencers
- Distinguish between individual topic areas and explain how they fit together
Speaker(s)
Experimental Study of Risk Information Amount and Location in Direct-to-Consumer Print Ads
Kathryn Aikin, PhD, MS
FDA, United States
Senior Social Science Analyst, Research Team Lead, OPDP, CDER
Visual Images of Prescription Drug Benefits in Direct-to-Consumer Television Advertisements
Helen W. Sullivan, PhD, MPH
FDA, United States
Social Science Analyst, OPDP, OMP, CDER
Utilization of Adequate Provision in Prescription Drug Broadcast Ads Among Low- and Non-Internet Users
Kevin R. Betts, PhD
FDA, United States
Social Science Analyst, OPDP, OMP, CDER
What Influences Healthcare Providers’ Prescribing Decisions? Results from a National Survey
Amie O'Donoghue, PhD
FDA, United States
Social Science Analyst, OPDP, OMP, CDER